Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer

NCT00284752 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Abraxane

Sponsor

Kaiser Permanente

Collaborators

[object Object]